Axiom Investors’s AtriCure ATRC Stock Holding History

Axiom Investors’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-21,225	Closed	-$847K	–	127
2020 Q3	$847K	Sell	21,225 -65,365	-75%	-$2.77M	0.01%	103
2020 Q2	$3.89M	Buy	+86,590	New	+$3.77M	0.08%	82
2017 Q4	–	Sell	-126,406	Closed	-$2.83M	–	143
2017 Q3	$2.83M	Sell	126,406 -51,786	-29%	-$1.17M	0.06%	108
2017 Q2	$4.32M	Buy	178,192 +22,153	+14%	+$471K	0.1%	95
2017 Q1	$2.99M	Sell	156,039 -22,265	-12%	-$390K	0.08%	101
2016 Q4	$3.49M	Buy	+178,304	New	+$3.23M	0.1%	94

Other funds holding ATRC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Axiom Investors's ATRC Position: Q4 2020 in Review

Axiom Investors sold out of AtriCure (ATRC) in Q4 2020, closing a stake of 21,225 shares — an estimated $847K sold.

Axiom Investors first reported a position in ATRC in Q4 2016 and held it in 6 quarters. The position peaked at $4.32M in Q2 2017. 198 funds tracked by Wall St. Rank hold ATRC as of Q4 2020.

Axiom Investors reported no remaining AtriCure position as of Q4 2020 after selling out during the quarter.
Axiom Investors sold 21,225 AtriCure shares in Q4 2020, an estimated $847K.
Axiom Investors first reported a position in AtriCure in Q4 2016 and held it in 6 quarters.
Axiom Investors's AtriCure position peaked at $4.32M in Q2 2017.
198 funds tracked by Wall St. Rank held AtriCure as of Q4 2020.

Based on Axiom Investors's 13F filing for Q4 2020, filed 12 Feb 2021.